Updates on capivasertib, belzutifan, talquetamab, & durvalumab
Lots of bite-size updates in this episode. Capitello-281: capivasertib + abiraterone (+ prednisone + ADT) Adjuvant Belzutifan + Pemroblizuma...
Radio and PodcastLive Radio & Podcasts
Science & Medicine
OncoPharm
Oncology Pharmacist & Educator. Talking all things #oncopharm
OncoPharm Podcast Guide
Listen to OncoPharm, a Science & Medicine podcast by OncoPharmPod. Stream 431 episodes in English, follow new audio stories, and play episodes online on Radio and Podcast.
Show Topic
Browse this show under Science & Medicine podcasts.
Episodes
20 episodes are loaded now from a catalog of 431. More episodes can be opened from this page.
Discover More
Explore Science & Medicine podcasts, India podcasts and English podcasts.
Episodes
20 of 431 episodesASCO '26
ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ova...
Pivekimab sunirine
Pivekimab sunirine, a novel CD-123 antibody drug conjugate is approved for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Also, what...
BCL2 & HER2 Targeting Agent Updates
The FDA has been a bunch of busy bees with new approvals: 1. Sonrotoclax, an exciting new BCL2 inhibitor approved for 3rd-line Mantle Cell L...
IMHOTEP, PJP, and more
This week's pod has lots of updates! IMHOTEP: Pre-operative doses of pembrolizumab lead to significant pCR rates in dMMR colon cancer. https...
Vepdegestrant
The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that a...
Targets Trop 2
This is our 1st in a series of podcasts/videos to role out once or twice a year on therapeutic targets in cancer. First up - Trop2 Check out...
Promising Pancreatic Cancer Data
This week we highlight some promising clinical research in the pancreatic cancer space. Daraxonrasib has shown OS benefit vs. chemo in the 2...
ICI-Induced T1DM
Bibliography: 1.. 2019 Systematic Review of Published Cases: https://doi.org/10.1111/dme.14050 2. Mass General Data & Publication: https://j...
Relacorilant
Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is ha...
HOPA 2026 Recap
Recapping what I learned at HOPA 2026: -Beyond steroids for irAs -IT chemo beyond methotrexate and cytarabine -Pre-emptive CMV management in...
Nivo-AVD Approval
Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?) in the PI. Also, brief NOLA preview...
Tazemetostat Withdrawl and RECITE
Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for p...
FDA Approval Updates Galore
Lots of FDA approval updates to discuss from the past few weeks: -Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metast...
BR.31 & ASCO GU '26
This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pemb...
Rezatapopt and Colchicine for Trametnib/Dabrafenib Pyrexia
An exciting new drug, rezatapopt, may be effective in restoring p53 activity in cancers - a possible major therapeutic breakthrough. Can col...
Perioperative Enortumab vedotin + Pembrolizumab
The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer pat...
Axi-Cel and 5-FU Label Changes
We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing)....
Core Communication Skills in Chemotherapy Education
A brief discussion of the Core Communication Skills* and how to incorporate them into a chemotherapy education session. *Rapport Building *A...
PATINA
Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 t...